Please login to the form below

Not currently logged in
Email:
Password:

Dutch companies partner on vaccines

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio. Pepscan focuses on protein mimicking technology for the generation of immune therapeutics.

Under the agreement, Immunovo will develop its therapeutic vaccine portfolio. Immunovo will pay an undisclosed cash sum to Pepscan and Pepscan will take a minority interest in Immunovo.

"Pepscan has recently refocused its R&D programme on the application of its proprietary CLIPSTM protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides," said Wim Mol, CEO of Pepscan.

"The agreement with Immunovo allows Pepscan to fully concentrate its resources on a focused execution of its research programme. We consider Immunovo an ideal partner to enhance the value of the therapeutic vaccine portfolio we have developed over the years."

Joost van Bree, CEO of Immunovo, said: "We are very pleased with the partnership with Pepscan on the therapeutic vaccine portfolio. Pepscan created a rich development pipeline of therapeutic vaccines, of which the most advanced product is in phase II clinical development.

"We are confident that with our specific expertise we will be able to expedite the development of this portfolio, which also includes a proprietary anti-VEGF-A vaccine that could be useful for the treatment of certain cancers."

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration.

28th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics